Angiosonics plans ultrasound clot-buster launch
This article was originally published in Clinica
Executive Summary
Angiosonics plans to launch its ultrasound clot-buster outside the US this summer. The US company has asked the FDA for permission to begin trials of the Acolysis system, which uses a high frequency ultrasound catheter to break down blood clots in coronary arteries. Angiosonics plans to pursue peripheral artery applications next year. Clinical trials have already begun in Tel Aviv, Israel, where 15 heart attack patients have been treated. Angiosonics plans to pursue peripheral artery applications next year.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.